Edwards Lifesciences (NYSE:EW – Free Report) had its price objective increased by Wells Fargo & Company from $113.00 to $121.00 in a report issued on Monday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.
EW has been the topic of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price objective (up from $101.00) on shares of Edwards Lifesciences in a report on Thursday, November 5th. Argus raised their target price on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 21st. Raymond James Financial raised their target price on Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Sanford C. Bernstein boosted their target price on shares of Edwards Lifesciences from $99.00 to $106.00 and gave the stock a “market perform” rating in a research report on Thursday, November 5th. Finally, Mizuho set a $120.00 price target on shares of Edwards Lifesciences in a research note on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $109.88.
Check Out Our Latest Stock Analysis on Edwards Lifesciences
Edwards Lifesciences Price Performance
Shares of NYSE:EW opened at $105.17 on Monday. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. The company has a market cap of $60.47 billion, a P/E ratio of 35.86, a PEG ratio of 2.81 and a beta of 0.85. Edwards Lifesciences has a 52 week low of $74.66 and a 52 week high of $108.00. The company has a 50-day moving average price of $91.51 and a 200 day moving average price of $86.68.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The company had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. Research analysts predict that Edwards Lifesciences will post 3.01 earnings per share for the current year.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 53,945 shares of company stock worth $5,498,306. 0.31% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Edwards Lifesciences
Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences in the second quarter worth $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at $1,274,082,000. Bank of America Corp DE acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at $605,397,000. Deutsche Bank AG purchased a new stake in Edwards Lifesciences during the 2nd quarter worth about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Edwards Lifesciences by 0.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock worth $496,503,000 after purchasing an additional 30,495 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
